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ABSTRACT -Seventy-five specimens of human breast tissue 
were checked for the presence of cellular retinoic acid-binding 
protein (cRABP). Fifty-two percent of the primary carcinomas 
and 43% of the dysplastic breast lesions (stage Mil) contained 
detectable amounts of cRABP, whereas no cRABP was found in 
normal tissue. Sucrose gradient centrifugation and electrophore-
sis on agarose were used for analysis of the presence of cRABP. 
The cRABP of human origin (normal uterus and neoplastic 
mammary tissue) differed in its mobility in agarose electro-
phoresis from that of rat testis cRABP-J Natl Cancer Inst 61: 
1375-1378, 1978. 
Retinol (vitamin A alcohol) is necessary for normal 
growth and differentiation of epithelial cells. Recent 
reports show that retinol and synthetic derivatives may 
prevent preneoplastic changes caused by carcinogens in 
epithelial cells (1-4). RA exhibits similar properties (5, 
6) as do synthetic analogs of RA (7, 8). Specific 
binding proteins have been demonstrated for both 
retinol and RA in various tissues (9, 10). A postulation 
is that both retinol and RA act through their respective 
binding proteins in a manner similar to that found for 
steroid hormones (11, 12). Ong and co-workers (13) 
showed the presence of cRABP in a limited number of 
breast and lung tumors. but not in the surrounding 
noncancerous tissue. Therefore. it was of interest to 
determine whether this binding protein was also pres-
ent in dysplastic cells. 
MATERIALS AND METHODS 
Chemicals.-All biochemical reagents were obtained 
from Sigma Chemical Co.. St. Louis. Missouri. The 
[I PH]RA (sp act. 1.3 Ci/mmole) was obtained from 
F. Hoffmann-La Roche. Ltd .. Basel. Switzerland. and 
was purified before each experiment. The [l PH]RA 
was stored in toluene at -20° C. Before use the toluene 
was blown off under argon and replaced by ethanol 
containing I mg (X-tocopherollm!. Agarose was pur-
chased from Seakem-Biomedical. Rockland. Maine. 
Preparation of cytosol.-Breast tissue specimens were 
obtained from patients during mastectomy and from 
biopsies. The tissue was morphologically characterized 
bv macroscopic examination at the time of surgery and 
b~' microscopic examination by the pathologist. The 
ti'ssue material was frozen immediately after excision 
and stored at -70° C. Subsequently. it was pulverized 
in liquid nitrogen. The tissue powder (1-1.5 g) was 
homogenized at pH 7.5 in ice-cold 50 mM Tris-HCI 
buffer in a ratio of I: 4 (wt/vol) and centrifuged at 
105.000Xg for I hour. The supernatant fraction. con-
taining 5-10 mg protein/mI. was recovered. Protein 
was determined according to the method of Lowry et 
al. (14). 
Assay for cRABP.-Aliquots. 250 or 500 1-'1. of the 
supernatant fraction were incubated at 4° C for 4 
hours in the dark with an equal volume of [3H]RA 
(10-7 M) in the assay buffer (50 mM Tris-HCl. pH 7.5). 
The incubation was carried out in the presence or 
absence of a 200-fold excess (2XIO-5 M) of unlabeled 
RA. The unbound ligand was removed by treatment of 
the solution with 250 or 500 1-'1 of a dextran-coated 
charcoal suspension (0.25% charcoal and 0.025% dex-
tran in 50 mM Tris-HCl buffer. pH 7.5). 
Sucrose gradient sedimentation.-Aliquots. 200 1-'1. 
of the supernatant fractions were layered on linear 
5-20% sucrose gradients and centrifuged at 4° C for 16 
hours at 50.000 rpm. 
Agarose electrophoresis.-For the electrophoresis the 
method described by Wagner (15) was used. Agar was 
replaced by agarose because agarose has lower electro-
osmosis. We prepared slab gels by heating 1 g agarose 
in 100 ml of 50 mM Michaelis buffer. pH 8.2. The clear 
solution was allowed to cool to 50° C and subsequently 
poured in a mold containing a glass plate (9.9X8.4 cm) 
to support the gel. Ten wells (50 1-'1) along the center 
line were punched out after the gel had formed. The 
glass plate containing the gel was placed on a brass 
plate coated with Teflon. and the temperature was 
lowered to 0° C by a circulating cooling mixture. We 
obtained electrical contacts by placing buffer-soaked 
filter paper at the long ends of the slabs. In the 
chamber was 100 mM Michaelis buffer. pH 8.2. The test 
solution was freed from unbound [3H]RA by the above 
charcoal method and introduced in the center wells 
(2X50 I-'lIsample). Electrophoresis was performed im-
mediately to avoid diffusion and run at 120 rnA and 
230 V for 90 minutes at 4° C. For analysis of the 
distribution of radioactivity. we sliced the gel into 
squares (9X3 mm). Only the anodic part of the plate 
was checked for specific RA binding. The gel slices 
were dissolved in Instagel and counted for radioactiv-
ity. We identified the peaks by running [3H]RA and 
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HSA plus [SH]RA simultaneously with tissue extracts 
incubated with radioactively labeled ligand. For the 
mixing experiment, a crude tumor extract (4 mg 
protein/ml) was mixed with a partially purified rat 
testis cRABP preparation (1.1 mg protein/ml) and 
analyzed as described above. 
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TEXT·FlGURE I.-Sucrose gradient sedimentation pattern of human 
breast tumor extracts. A: Stage Mil containing cRABP. B: Primary 
carcinoma containing cRABP in high quantity. C: Stage Mil with 
no detectable amounts of cRABP. For each expt. an average of 
4-10 mg protein/ml was used. Pat. = patient. 
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RESULTS 
Sucrose gradient sedimentation of breast tissue sam-
ples incubated with [~H]RA revealed two peaks of 
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TEXT·FtGURE 2.-A: Sucrose gradient sedimentation pattern of a pri-
mary tumor extract (4.6 mg protein/ml). which was centrifuged in 
the absence (0--0) and presence (e - - - e) of 200-fold ex-
cess unlabeled RA. B: Agarose electrophoresis of the same tissue 
sample (4.6 mg protein/ml) as in panel A. Extract was subjected 
to electrophoresis in the absence (0---0) and presence 
(e- - - e) of 200-fold excess unlabeled RA. Arrow indicates start 
of electrophoretic migration. Pat. = patient. 
VOL. 61. NO.6. DECEMBER 1978 
Acid-Binding Protein In Human Breast Cancer and Dysplasia 1377 
A 
1.00 (f) e 
0.80 
0.60 
0.40 
0.20 
c 
.2 B ~ 1.00 Ef) e 
! 
'0 0.80 .~ 
u 
'(5 
0.60 c 
:: 
.. 
""%' 0.40 (WI 
~ 
E 
Q. 0.20 u 
(WI 
51 
>C 
C 
1.00 (f) e 
0.80 
0.60 
0.40 
0.20 
o 4 8 12 16 20 
FRACTION NUMBER 
TEXT·FlGURE 3.-Mixing expt with extracts from rat testis and hu-
man breast cancer. Agarose electrophoresis was used to analyze for 
cRABP. A: cRABP from rat testis (1.1 mg protein/mI). B: cRABP 
from human breast cancer (4.6 mg protein/ml). C: Analysis of the 
mixed solutions from rat testis and human breast cancer. Samples 
run in absence (0--0) and presence (e- - - e) of 200-fold 
excess unlabeled RA. Arrows indicate start of electrophoretic 
migration. 
radioactivity sedimenting at 2S and 4.6S (text-fig. IA). 
The binding at 2S represented the cRABP inasmuch as 
this peak could be abolished by a 200-fold excess of 
unlabeled RA. This inhibition was specific for RA 
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inasmuch as a similar excess of retinol showed no 
inhibition. According to Sani and Hill (16), the 4.6S 
peak represented nonspecific binding to serum al-
bumin. The pattern in text-figure IA was the one 
encountered in most tissue samples analyzed. Text-
figure IB exhibits a profile typical of a biopsy sample 
with a very high concentration of cRABP, whereas the 
tissue sample shown in text-figure Ie contained no 
detectable amounts of cRABP. The criterion for the 
presence of a specific RA binding was the abolishment 
of the 2S peak by an excess of unlabeled RA. 
Text-figure 2A demonstrates the sedimentation pat-
tern and text-figure 2B shows the electrophoretic mi-
gration of cRABP obtained from a mammary tumor. 
With both methods, the peak characteristic for cRABP 
was very prominent. The peak at fraction II (text-fig. 
2B) disappeared completely with an excess of unlabeled 
RA. The radioactivity found in fractions 3-5 rep-
resented a mixture of free and unspecifically bound 
ligand to HSA. 
On agarose electrophoresis, cRABP of human origin 
did not migrate to the same position as did the rat 
testis cRABP. 
Text-figure 3A demonstrates the electrophoretic pro-
file for cRABP obtained from rat testis, and text-figure 
3B shows the electrophoretic profile obtained for 
cRABP from human breast tumor. The maximum 
radioactivity in the rat testis material for cRABP was 
found in fraction 7 as compared to fraction II of the 
human sample (text-fig. 3B). The mixing experiment 
suggested that cRABP from the two sources was 
different (text-fig. 3C). Such a difference went unde-
tected by sucrose gradient centrifugation of the rat 
testis and the human tumor extracts. The electro-
phoretic migration pattern of cRABP (text-fig. 3B), 
obtained from a primary carcinoma, was not restricted 
to human breast cancer. Human uterus extracts, which 
contain the RA-binding protein (17), incubated with 
PH]RA and subjected to agarose electrophoresis, 
showed the ligand specifically bound also at fraction 
II (results not shown). Furthermore, the electropho-
retic profile of extracts from human breast tumors in 
stage MIl (proliferation of ductules in breast tissue 
plus intraductal epithelial proliferation) was the same 
as in the primary carcinomas (results not shown). 
Table I shows the distribution of cRABP in breast 
dysplasias, with different proliferative activities, and in 
primary carcinomas. In 52% of the carcinomas, cRABP 
TABLE l.-Distribution of cRABP in dysplastic and neoplastic 
human mammary tissue 
Type of No. of No. of tissue 
extracts con- Percent tissue, stage" biopsies taining cRABP 
MI-F 16 0 0 
MI 16 0 0 
MIl 14 6 43 
CA 29 15 52 
• Classified according to the criteria in (18); MI-F, simple 
dysplasia with extensive fibrosis; MI, simple dysplasia; MIl, 
proliferative dysplasia; and CA, primary carcinoma. 
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actIVity was detected. Also, 43% of the specimens with 
pronounced epithelial proliferation (stage MIl) con-
tained cRABP. Neither of the 16 samples graded MI-F 
(fibrosis and atrophy of the breast tissue) nor MI 
(proliferation of ductules in breast tissue) exhibited 
detectable amounts of cRABP. 
DISCUSSION 
These results add more information to our under-
standing of the distribution of cRABP in the dif-
ferent stages of breast tumor formation. In contrast 
to Dng et al. (13), we found cRABP in only 52% of the 
invasive carcinomas examined. Therefore, cRABP can-
not necessarily be called an obligatory product of 
carcinoma formation. Also, we detected the binding 
protein in less than half of the breast lesions of 
proliferative dysplasia (stage MIl), which are con-
sidered as being possibly precancerous. None of the 
tissue specimens graded MI-F, which was considered 
normal tissue, contained cRABP (table 1). 
Retinoids obviously influence the differentiation of 
epithelial cells (6, 8). Attempts to elucidate their mode 
of action in relation to the occurrence of steroid 
receptors in breast carcinomas are in progress in this 
laboratory. These studies and those concerning the 
adenylyl cyclase protein kinase system as biochemical 
markers (19, 20) may provide a better understanding of 
the many factors influencing the development of hu-
man breast tumors. 
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